Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Need to know how Cryoport’s cryogenic logistics deals with FDA requirements, capital spending, or new biotech partnerships? Each document is packed with technical details that make traditional dry ice look simple. That complexity is exactly why investors search for “Cryoport SEC filings explained simply”.
Stock Titan solves the problem. Our AI reads every Cryoport annual report 10-K simplified, parses each Cryoport quarterly earnings report 10-Q filing, and flags Cryoport 8-K material events explained in minutes. Want to track management confidence? Receive real-time alerts on Cryoport Form 4 insider transactions real-time, including every Cryoport executive stock transactions Form 4.
Here’s what you can do in one place:
- Compare liquid-nitrogen shipper revenue lines across quarters using our Cryoport earnings report filing analysis.
- Monitor Cryoport insider trading Form 4 transactions before key trial milestones are announced.
- Review governance details inside the Cryoport proxy statement executive compensation without combing through appendices.
- Save hours by understanding Cryoport SEC documents with AI summaries that translate complex supply-chain disclosures into plain language.
Whether you’re modeling future demand for cell & gene therapy logistics or checking covenant compliance, you’ll find comprehensive coverage of 10-K, 10-Q, 8-K, S-1, and ownership filings—updated the moment they hit EDGAR. Make faster, well-informed decisions with unbiased AI insight on every Cryoport filing.
Cryoport (CYRX) filed a routine Form 4 detailing insider activity by President & CEO Jerrell Shelton. On 06/24/2025 he exercised 16,344 options at $5 and immediately sold the same number of shares at a weighted-average $7.06, generating roughly $115 k in gross proceeds. On 06/25/2025 he exercised an additional 25,000 options without selling. Post-transaction ownership stands at ~937,000 shares. The sale represents less than 2% of his holdings and was executed under a pre-established 10b5-1 plan, indicating no material shift in insider sentiment.
CryoPort (NASDAQ:CYRX) filed a Form 4 reporting insider activity by director Ramkumar Mandalam on 24 Jun 2025.
The director exercised 20,000 options at $3.07, then sold 13,321 shares at a weighted-average price of $7.015. Net effect is a 6,679-share increase, lifting direct ownership 10% to 73,056 shares. Remaining derivative holdings total 60,000 options.
The open-market sale represents about 18% of his post-transaction stake and generated roughly $93k in proceeds. All trades were executed under a Rule 10b5-1 plan adopted 10 Jun 2025.
No other executives were involved and no strategic disclosures accompanied the filing.
CryoPort, Inc. (CYRX) – Form 144 Filing Overview
An insider, identified in the filing as Ramkumar Mandalam, has filed a Form 144 indicating his intent to sell 13,321 common shares of CryoPort through broker Morgan Stanley Smith Barney on or about 24 June 2025. Based on the stated aggregate market value of $87,385.76, the planned transaction equates to an implied price of roughly $6.56 per share.
The filing also discloses that Mandalam has already disposed of 16,334 shares in four separate transactions between 9 June 2025 and 13 June 2025, generating gross proceeds of $115,000 +. Combining past and proposed sales, total recent dispositions amount to 29,655 shares.
Relative to CryoPort’s 50.14 million shares outstanding, the proposed sale represents approximately 0.03 % of total shares, and the cumulative three-month sales represent about 0.06 %, suggesting limited dilution risk. The shares to be sold were acquired via a same-day stock-option exercise paid in cash. No adverse, non-public information is asserted by the filer, as required under Rule 144.
For investors, Form 144 signals potential insider sentiment changes, but the modest size versus the share count indicates a low direct share-supply impact. Nevertheless, repeated sales within a short window may warrant monitoring for future filings.
Jerrell Shelton, President, CEO, and Director of Cryoport (CYRX), executed significant stock option exercises and sales between June 17-20, 2025, as part of a pre-planned trading arrangement.
Key transactions include:
- Exercised options for 389,720 total shares at $5.00 strike price
- Sold 339,720 shares at weighted average prices between $6.33-$6.97
- Retained 50,000 shares from initial exercise
- Maintained beneficial ownership of 912,419 shares post-transactions
The transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025. The exercised options were originally granted in August 2015 with a 48-month vesting schedule. After all transactions, Shelton continues to hold 166,344 unexercised stock options with an August 2025 expiration date.
FAQ
What is the current stock price of Cryoport (CYRX)?
What is the market cap of Cryoport (CYRX)?
What is Cryoport Inc?
What core services does Cryoport offer?
How does Cryoport support cell and gene therapies?
Who are Cryoport's primary customers?
What makes Cryoport's technology unique?
In which markets does Cryoport operate?
How does Cryoport ensure regulatory compliance?
What distinguishes Cryoport in a competitive market?
